Clinical research of intraperitoneal implantation of sustained-release 5-fluorouracil in advanced colorectal cancer

Table 4 Toxic and adverse effects in patients in the two study groups (according to NCI-CTCAE v3.0)

Parameter	Group 1					Group 2
Parameter	I	II	III	IV	V	I	II	III	IV	V
WBC	4	2	1	0	0	5	1	0	0	0
Platelet count	1	1	0	0	0	2	0	0	0	0
Bleeding	0	0	0	0	0	0	0	0	0	0
Renal toxicity	0	0	0	0	0	0	0	0	0	0
Hepatotoxicity	1	1	0	0	0	2	1	0	0	0
Fever (post-operation >7 days)	3	0	0	0	0	2	1	0	0	0
Infection	9	3	0	0	0	12	2	0	0	0
Diarrhea	0	0	0	0	0	0	0	0	0	0
Vomiting	1	0	0	0	0	1	1	0	0	0
Constipation	0	0	0	0	0	1	0	0	00	0
Cardiac function	0	0	0	0	0	0	0	0	0	0
Pneumonia (X-ray)	4	0	0	0	0	4	1	0	0	0
Peripheral numbness	0	0	0	0	0	0	0	0	0	0
Allergic reaction	0	0	0	0	0	1	0	0	0	0
Abdominal ache (post-operation >7 days)	5	2	0	0	0	5	1	0	0	0

When toxic and adverse events were classified according to the NCI-CTCAE v3.0, there were no significant differences between the two groups. The most common were 7 cases of abdominal ache in group 1 and 6 cases in group 2; 2 cases of hepatotoxicity in group 1 and 3 cases in group 2; and 12 cases of infection in group 1 and 14 cases in group 2. All of the reported events were grade I or II and therefore were mild or moderate
NCI-CTCAE National Cancer Institute common terminology criteria for adverse events

ISSN: 1477-7819